XXXX : Clinical spectrum and long-term outcome from a developing country perspective.

@entity1 @entity410 @entity64 @entity1024 @entity146 @entity5 @entity73 @entity3 @entity8231 @entity5433 @entity2414 @entity14204
INTRODUCTION: @entity14204 ( @entity14204 ) is characterized by rapidly progressive @entity2414 , @entity146 symptoms and @entity410 . We describe the clinical spectrum, underlying etiology and long-term follow-up of @entity1 with @entity14204 from India. MATERIALS AND METHODS: This prospective study included @entity1 during the period of January 2009 and December 2011 with the clinical features consistent with @entity14204 with one or more of the following: (1) Magnetic resonance imaging (MRI) evidence of temporal lobe involvement; (2) cerebrospinal fluid inflammatory abnormalities, or (3) detection of antineuronal antibodies. Patients with @entity3 , infection, metabolic and nutritional deficits, @entity64 , were excluded. RESULTS: There were 16 @entity1 (9 females), mean age of presentation was 36.6 years (range 15-69 years). The mean duration of symptoms before presentation was 11 months (range 5 days-2 years). The most common symptom at presentation was @entity73 in 7 @entity1 followed by @entity410 in 5 and behavioral changes in three. Nine @entity1 had @entity410 , 11 had change in behavior, language involvement in eight, cerebellar features in 3 and @entity5433 in two. Four @entity1 had associated @entity5 , 3 of four presented with neurological symptoms and on investigations found to be have @entity5 . Antineuronal antibody testing was done in 6 of 12 non @entity8231 and two @entity8231 @entity1 , one positive for @entity1024 and one for anti-Hu antibody. MRI brain showed typical fluid attenuated inversion recovery or T2 bilateral temporal lobe hyperintensities in 50% of @entity1 . At a mean follow-up of 21 months (3-36 months), 10 @entity1 improved, 4 @entity1 remained same and two @entity1 expired. CONCLUSION: Early recognition of @entity14204 is important based upon clinical, MRI data in the absence of antineuronal surface antibody screen in developing nations. Early institution of immunotherapy will help in improvement in outcome of these @entity1 in long-term.
